AI News Sentiment & Analysis
IN8bio, Inc. (INAB) — AI News Sentiment & Analysis
3 recent AI analyses of IN8bio, Inc. (INAB) stock news and press releases, with sentiment and confidence scoring updated continuously.
IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026
BullishClinical ResultsPositive updated clinical data from Phase 1/2 studies of DeltEx DRI in glioblastoma, demonstrating improved median overall survival and progression-free survival. (Timing: Next regulatory steps and further clinical development are expected over the next 12-24 months.)Jun 1, 2026IN8bio Presents New Translational Data Demonstrating DeltEx DRI Reshapes the Immune Landscape in Glioblastoma
BullishClinical ResultsPositive translational clinical data providing mechanistic insights into DeltEx DRI's efficacy in glioblastoma, building on previously reported survival improvements. (Timing: Ongoing Phase 1 and 2 trials with future studies are anticipated over the next 12-24 months.)May 14, 2026IN8bio Reports Fourth Quarter and Full-Year 2025 Financial Results - Highlights Durable Survival Improvements in Glioblastoma, Advancing Pipeline and Strengthened Financial Position for 2026
BullishPositive updated Phase 1/2 clinical data for INB-200/400 in glioblastoma, demonstrating significantly improved survival rates and a favorable safety profile. The company also secured substantial financing to extend its cash runway. (Timing: Additional clinical updates on GBM programs expected mid- and late-2026, with FDA guidance on regulatory pathway by H2 2026.)Mar 12, 2026
Want the full picture?
These are AI-read press-release catalysts. Sign up to see complete investment theses, valuation rationales, entry/exit strategies, and get real-time alerts.
Sign Up for FreeFrequently Asked Questions
Is IN8bio, Inc. (INAB) bullish or bearish right now?
AI Sentiment on INAB: 3 Bullish.
What was the latest AI analysis for IN8bio, Inc. (INAB)?
The latest analysis was published on 6/1/2026 with the headline: "IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026".
How does Bekodia analyze IN8bio, Inc. (INAB) stock?
Bekodia uses advanced AI models to process IN8bio, Inc. (INAB) press releases and news in real-time, extracting sentiment, confidence scores, and key investment catalysts while filtering out market noise.